Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant presents with at least 3 episodes of non-bilious, non-bloody vomiting within the 24 hours prior to visiting the physician's office. The participant has at least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort) within 3 hours prior to visiting the physician's office~* The participant has mild-to-moderate dehydration~* The participant had at least 1 episode of non-bloody diarrhea within the 24 hours prior to the visiting the physician's office~Exclusion Criteria:~* The participant has severe dehydration or severe malnutrition~* The participant who has vomiting and clinical symptoms for longer than 72 hours prior to the baseline physician's office visit~* The participant needs intravenous (IV) fluid replacement~* The participant has chronic severe diarrhea, a previous history of Helicobacter pylori infection or received treatment for H. pylori-induced gastritis, active peptic ulcer, celiac disease, Crohn's disease, ulcerative colitis, eosinophilic esophagitis, malabsorption, short bowel syndrome, post-viral gastroparesis, cyclic vomiting syndrome, or previous gastrointestinal surgery~* The participant has upper respiratory symptoms such as cough, congestion, otitis media or pharyngitis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Oral Rehydration Therapy (ORT) + Domperidone (Type: EXPERIMENTAL): Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
- Oral Rehydration Therapy + Placebo (Type: EXPERIMENTAL): Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).